(Q39974678)

16 September 2017

title

Comparative study of four different assays for the detection of binding antibodies against interferon-beta (English)

1 reference

16 September 2017

8

1 reference

16 September 2017

C Gneiss

1

1 reference

16 September 2017

M Brugger

2

1 reference

16 September 2017

A Millonig

3

1 reference

16 September 2017

A Fogdell-Hahn

4

1 reference

16 September 2017

D Rudzki

5

1 reference

16 September 2017

J Hillert

6

1 reference

16 September 2017

T Berger

7

1 reference

16 September 2017

F Deisenhammer

9

1 reference

16 September 2017

language of work or name

1 reference

5 June 2008

1 reference

Multiple Sclerosis Journal

16 September 2017

published in

1 reference

16 September 2017

volume

14

1 reference

16 September 2017

issue

6

1 reference

16 September 2017

page(s)

830-836

1 reference

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

An Analysis of Neutralization Reaction of Interferon by Antibody: A Proposal on the Expression of Neutralization Titer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Epitope specificity of neutralizing antibodies against IFN-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Immunoglobulin Subclasses in Patients with Neutralizing and Nonneutralizing Antibodies Against IFN-β1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

Interferon-β antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508089228

21 January 2018

Identifiers

DOI

10.1177/1352458508089228

1 reference

16 September 2017

1 reference